KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Operating Expenses (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Operating Expenses for 8 consecutive years, with -$130.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 3.94% year-over-year to -$130.4 million, compared with a TTM value of $129.2 million through Dec 2025, up 88.37%, and an annual FY2025 reading of $129.2 million, up 88.37% over the prior year.
  • Operating Expenses was -$130.4 million for Q4 2025 at Esperion Therapeutics, down from $97.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $97.3 million in Q3 2025 and bottomed at -$135.8 million in Q4 2024.
  • Average Operating Expenses over 5 years is $51.5 million, with a median of $70.6 million recorded in 2021.
  • The sharpest move saw Operating Expenses tumbled 281.97% in 2024, then soared 43.76% in 2025.
  • Year by year, Operating Expenses stood at $71.0 million in 2021, then fell by 13.65% to $61.3 million in 2022, then rose by 21.66% to $74.6 million in 2023, then crashed by 281.97% to -$135.8 million in 2024, then grew by 3.94% to -$130.4 million in 2025.
  • Business Quant data shows Operating Expenses for ESPR at -$130.4 million in Q4 2025, $97.3 million in Q3 2025, and $75.3 million in Q2 2025.